Dr Richard Harbottle

Company: German Cancer Research Centre (DKFZ)

Job title: Head of DNA Vector Research

Seminars:

Next-Generation DNA NanoVectors – An Alternative Vector Platform for the Safe, Rapid, and Persistent Manufacture of Recombinant T cells for Autologous T Cell Immunotherapy 11:30 am

A novel non-integrating minimally sized DNA vector platform named nS/MARt was used to efficiently engineer human T lymphocytes When nS/MARt technology was combined with GMPcompliant MaxCyte Flow Electroporation®, the production of clinical scale recombinant CAR T cells with enhanced antitumor activity was achieved in only five days The key advantages of the nS/MARt vector platform…Read more

day: Day 1 – Track B – Morning